Intra-individual variation of circulating tumour DNA in lung cancer patients.
Intra-individual variation
circulating tumour DNA
digital PCR
lung cancer
next-generation sequencing
Journal
Molecular oncology
ISSN: 1878-0261
Titre abrégé: Mol Oncol
Pays: United States
ID NLM: 101308230
Informations de publication
Date de publication:
10 2019
10 2019
Historique:
received:
16
05
2019
revised:
05
07
2019
accepted:
12
07
2019
pubmed:
16
7
2019
medline:
1
7
2020
entrez:
16
7
2019
Statut:
ppublish
Résumé
Circulating tumour DNA (ctDNA) has been increasingly incorporated into the treatment of cancer patients. ctDNA is generally accepted as a powerful diagnostic tool, whereas the utility of ctDNA to monitor disease activity needs to be fully validated. Central to this challenge is the question of whether changes in longitudinal ctDNA measurements reflect disease activity or merely biological variation. Thus, the aim of this study was to explore the intra-individual biological variation of ctDNA in lung cancer patients. We identified tumour-specific mutations using next-generation sequencing. Day-to-day and hour-to-hour variations in plasma concentrations of the mutant allele and wild-type cell-free DNA (cfDNA) were determined using digital PCR. The levels of the mutant alleles varied by as much as 53% from day to day and 27% from hour to hour. cfDNA varied up to 19% from day to day and up to 56% from hour to hour, as determined using digital PCR. Variations were independent of the concentration. Both mutant allele concentrations and wild-type cfDNA concentrations showed considerable intra-individual variation in lung cancer patients with nonprogressive disease. This pronounced biological variation of the circulating DNA should be investigated further to determine whether ctDNA can be used for monitoring cancer activity.
Identifiants
pubmed: 31306545
doi: 10.1002/1878-0261.12546
pmc: PMC6763781
doi:
Substances chimiques
Circulating Tumor DNA
0
DNA, Neoplasm
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2098-2106Informations de copyright
© 2019 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
Références
Science. 2004 Jun 4;304(5676):1497-500
pubmed: 15118125
Nat Med. 2008 Sep;14(9):985-90
pubmed: 18670422
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
N Engl J Med. 2009 Sep 3;361(10):947-57
pubmed: 19692680
Ann Clin Biochem. 2010 May;47(Pt 3):253-8
pubmed: 20421309
Nat Biotechnol. 2011 Jan;29(1):24-6
pubmed: 21221095
Anal Chem. 2011 Nov 15;83(22):8604-10
pubmed: 22035192
Nature. 2013 May 2;497(7447):108-12
pubmed: 23563269
Clin Chem. 2013 Aug;59(8):1228-37
pubmed: 23603797
Clin Cancer Res. 2014 Mar 15;20(6):1698-1705
pubmed: 24429876
Cancer. 2014 Dec 15;120(24):3896-901
pubmed: 25103305
Future Oncol. 2015;11(11):1611-23
pubmed: 26043215
Sci Transl Med. 2015 Aug 26;7(302):302ra133
pubmed: 26311728
Nat Commun. 2015 Nov 04;6:8760
pubmed: 26530965
J Thorac Oncol. 2016 Oct;11(10):1682-9
pubmed: 27468938
Int J Sports Physiol Perform. 2017 Apr;12(4):455-462
pubmed: 27617389
Biomol Detect Quantif. 2014 Aug 20;1(1):8-22
pubmed: 27920993
Crit Rev Clin Lab Sci. 2017 May;54(3):205-218
pubmed: 28393575
Thorac Cancer. 2017 Jul;8(4):312-319
pubmed: 28437026
Br J Cancer. 2017 Aug 22;117(5):704-709
pubmed: 28683468
Cancer Med. 2017 Oct;6(10):2297-2307
pubmed: 28940814
Oncotarget. 2017 Aug 7;8(36):60291-60298
pubmed: 28947971
Oncotarget. 2017 Jul 10;8(38):63846-63856
pubmed: 28969034
Front Med (Lausanne). 2018 Jan 30;5:9
pubmed: 29441349
Cancer J. 2018 Mar/Apr;24(2):93-103
pubmed: 29601336
Oncotarget. 2018 Jul 24;9(57):31066-31076
pubmed: 30123427
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv192-iv237
pubmed: 30285222
Am J Hum Genet. 1999 Jan;64(1):218-24
pubmed: 9915961